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Purpose: To evaluate the efficacy of a selective cyclooxyge-
nase-2 (COX-2) inhibitor in rat bladder cancer chemoprevention, 
as well as to assess the relevance of inflammation, proliferation 
and oxidative stress in tumor growth and in its prevention.
Results: The main findings were: (I) the incidence of carci-
noma was: control: 0% (0/8); BBN: 65% (13/20); CEL: 0% 
(0/8) and BBN + CEL: 12.5% (1/8); (II) the mean tumor volume 
per rat with tumor and per tumor were significantly lower in the 
BBN + CEL group (21.2 and 5.3 ± 0.4 mm3) vs. BBN (138.5 ± 
7.5 and 112.5 ± 6.4 mm3); (III) the incidence of pre-neoplasic 
(hyperplasia and dysplasia) and neoplasic (papillary tumors and 
carcinoma in situ—CIS) lesions were notoriously reduced in the 
CEL + BBN treatment; (IV) CEL significantly reduced serum 
TGFβ1 and CRP and increase TNFα and IL-1β (p < 0.001); 
(V) CEL reduced MDA formation in serum (p < 0.001) and liver 
(p < 0.05) and also showed a trend to reduction in kidney.
Methods: Drug treatments were performed during the first 
8 w, followed by 12 w for tumor expression/prevention, in 
the following groups: control—vehicle; carcinogen—0.05% 
of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN); celecoxib 
(CEL)—10 mg/kg/day and preventive CEL + BBN. The blad-
ders were analyzed for number and volume of tumor and nature 
of urothelium lesions. Serum was assessed for markers of inflam-
mation, proliferation and redox status.
Conclusions: Celecoxib has demonstrated an outstanding 
inhibitory effect on bladder cancer chemoprevention, which 
might be due to its expected anti-inflammatory actions, as well as 
by anti-proliferatory and antioxidant actions. This data supports 
a pivotal role of cancer chemoprevention strategies based on 
COX-2 inhibition.
Introduction
Bladder cancer remains a huge concern for the medical commu-
nity because of its malignancy, as well as high mortality, incidence 
and prevalence rates.1,2 Furthermore, recurrence rates are also high, 
explaining that prevalence exceeds the primary incidence.3,4 It is 
the fourth most common tumor in men and the eighth in women, 
accounting for 5–10% of all malignancies in Western countries.2 
Excepting for superficial forms, bladder cancer prognosis is poor, 
particularly when lately diagnosed or inadequately treated, and is 
associated with high socioeconomic cost.1,5,6 Despite the advances 
in medical care, the conventional methods of surgery, chemo-
therapy and radiotherapy have not impacted greatly on the general 
morbidity and mortality.7,8 Thus, preventive strategies are crucial 
for the management and treatment of bladder cancer, which will 
depend on a better elucidation of the mechanisms underlying 
cancer lesions development. Exogenous factors, such as cigarette 
smoking, which accounts for a huge percentage of cases, as well as 
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occupational carcinogens, such as aromatic amines and polycyclic 
aromatic hydrocarbons, are important determinants of the disease 
appearance.9,10 However, apart from the genetic features already 
characterized,11 the cellular and molecular mechanisms might 
involve inflammatory, proliferative and oxidative stress pheno-
menon that should be better elucidated.
The carcinogen-induced model of bladder cancer with N-butyl-
N-(4-hydroxybutyl) nitrosamine (BBN) in rats is a valuable 
experimental tool to study human cancer development, namely 
due to similar histological features with the human transitional 
cell carcinoma.12 Urothelial transitional cell carcinoma is the 
predominant pathological lesion. The malignant transformation 
is a continuous process that includes dysplasic and proliferative 
epithelial abnormalities, pre-neoplasic changes and malignant 
lesions (papiloma and carcinoma).2,13,14 This model should also 
be important to evaluate the efficacy of modern therapeutic strate-
gies.15 An early treatment with drugs that reverse these molecular 
and morphological pathways might hypothetically prevent the 
bladder cancer. Pre-clinical studies using green tea polyphenols, soy 
products, vitamins, selenium and nonsteroidal anti-inflammatory 
drugs (NSAIDs) demonstrate that bladder cancer is responsive to 
prevention strategies.16,17
As previously suggested, bladder cancer development might 
be linked with inflammatory stimuli.18 The prostaglandin G/H 
synthase classe, which include the cyclooxygenase-1 (COX-1) and 
COX-2 isoforms, are key enzymes in the synthesis of prostaglan-
dins from arachidonic acid. COX-1 is expressed in nearly all tissues 
and is thought to be responsible for the low levels of prostaglandins 
needed for tissue maintenance and homeostasis. On the contrary, 
COX-2 is not expressed in most tissues under normal conditions, 
but expression is rapidly induced by growth factors or agents that 
cause tissue irritation or inflammation.19 The role of COX-2 
in acute inflammatory processes contribute at multiple points 
throughout tumorigenesis, including premalignant hyperproli-
feration, transformation, maintenance of tumor viability, growth, 
invasion and metastic spread.20
According to several studies, the modulation of mice COX-2 
levels and/or activity, by genetic deletion or chemical inhibition, 
has decreased tumors development. Therefore, the use of selec-
tive COX-2 inhibitors (Coxibs) for chemoprevention was already 
tested in other types of cancer,21-23 but its efficacy in bladder 
cancer has been poorly investigated.
This work intend to discuss the hypothesis that aberrant induc-
tion of COX-2 and upregulation of the prostaglandin cascade play 
a significant role in carcinogenesis, a process know as “inflam-
mogenesis of cancer.” In order to do so, we have used a rat model 
of bladder cancer to test the chemopreventive effect of a selective 
COX-2 inhibitor (Celecoxib), as well as to assess the relevance of 
inflammation, proliferation and oxidative stress in tumor growth 
and in its potential prevention.
Results
Tumor chemoprevention data. Body weight and beverage 
consumption. No relevant changes were obtained between the 
groups during the study concerning body weight and beverage 
consumption. However, there was a reduction in beverage consump-
tion (data not shown) in the CEL + BBN rats vs. the BBN animals 
between the Ti and the Tf (8–20 w), which cannot explain per se 
the CEL efficacy on cancer chemoprevention because during that 
period all the animals were only under water consumption (BBN 
treatment was performed between the T0 and the Ti).
Macroscopic evaluation. All formaldehyde pre-fixated bladders 
were opened and analyzed macroscopically for wall (urothelium) 
texture, thickness and vascularization (Fig. 1). The percentage of rats 
with tumors in each group, the nr of tumors per rat with tumor, as 
well as the mean tumor volume per rat and per tumor were then 
evaluated (Table 1). All the bladders from the control animals have 
revealed a pattern of normality, with absence of any type of malig-
nity. The wall texture, thickness and vascularization were normal 
(Fig. 1A). Similar profile was found for the CEL group, with limpid, 
translucent and tiny bladders, without presence of any abnormal 
mass or vascularization (Fig. 1B). In the BBN group, however, 
65.0% (13 in 20) of the rats had bladder tumors, almost all easily 
seen by macroscopic analysis. The bladder walls were thicker, with 
new or enlarged small vessels, suggesting neo-angiogenesis, and 
there was unequivocal formation of tumor, some of them of relevant 
volume, also visible in the whole-bladder (Fig. 1C and D). In the 
CEL + BBN group, excepting one case, all bladder shown a similar 
pattern to those seen for the control or CEL rats, with macroscopi-
cally unrecognized signs of abnormality (Fig. 1E and F).
Quantitative evaluation. In the control group, as expected, no 
rat developed bladder cancer. The same profile was found for the 
CEL animals. In the BBN group (n = 20 rats), the percentage of 
rats with bladder cancer was 65.0% (13 in 20), with a mean of 1.2 
± 0.1 tumors per rat with tumor. Furthermore, the mean tumor 
volume per rat with tumor (in 13 rats) was 138.5 ± 7.5 mm3 and 
the mean tumor volume per tumor (in 16 tumors) was 112.5 ± 
6.4 mm3 (Table 1). In the CEL + BBN group, there was notorious 
bladder cancer prevention, with a percentage of tumors in the 
group of 12.5% (1 in 8), which corresponds to only one rat with 
cancer in the group universe of eight animals. In agreement, the 
mean tumor volume per tumor (in four tumors of only one rat) 
was 5.3 ± 0.4 mm3 and the mean tumor volume per tumor was 
21.2 mm3 (Table 1).
Qualitative evaluation. Concerning the microscopic analysis of 
urothelium layer and urothelial tumors, the control and the CEL 
rats have shown normal patterns (Fig. 2A and B, respectively). 
The bladder from control animals had no signs of pre-neoplasic 
lesions (neither hyperplasia nor dysplasia), as well as those from 
the CEL rats (Table 1). In the carcinogen (BBN) group, there was 
evident malignant transformation, including hyperplasia (100%) 
and dysplasia (100%), present in all the animals, including those 
without tumor formation. Furthermore, there were also malignant 
lesions, papillary, infiltrative and CIS (Table 1 and Fig. 2C and D). 
The use of CEL (group CEL + BBN) has notoriously prevented 
bladder cancer development. Therefore, as above mentioned, only 
one bladder of the eight rats from the group have shown cancer 
development (12.5% of the rats from the group) (Table 1). Apart 
from the rat with tumors (all papillary), whose urothelium has 
demonstrated hyperplasia and dysplasia, without infiltrative or CIS 
(Table 1 and Fig. 2E), all the other rats have presented a normal 
www.landesbioscience.com Cancer Biology & Therapy 1617
Mechanisms of bladder cancer chemoprevention by COX-2 inhibition
Proliferation, inflammation and redox status profiles. In the 
BBN group there was a significant increment in serum TGFβ1 
(transforming growth factor β-1) (p < 0.01) and C-reactive 
protein (CRP) (p < 0.001) when compared with the control group 
urothelium profile (there was only low-grade hypertrophy in two 
of those seven animals) (Table 1 and Fig. 2F).
The lungs, stomach, liver, kidneys and intestines were normal 
on gross inspection and on histological examination.
Figure 1. Macroscopic histomorphology. All the bladders from the control (A) and CEL (B) treated-rats have revealed a pattern of total normality. In the 
BBN group (C and D), 65.0% of the rats had bladder tumors, almost all easily seen by macroscopic analysis. The bladder walls were thicker, with new 
or enlarged small vessels, suggesting neo-angiogenesis and there was unequivocal formation of tumor. In the CEL + BBN group (E and F), all bladders, 
excepting one case, shown a macroscopic normal pattern.
Table 1  The effects of a selective cyclooxygenase-2 inhibitor on bladder cancer chemoprevention: 
Macroscopic (quantitative) and microscopic (qualitative) evaluation of urothelium lesions
Macroscopy (quantitative) Control (n = 8) BBN (n = 20) CEL (n = 8) CEL + BBN (n = 8)
Tumor number
% rats with tumor 0 (13 in 20) 65.0% 0 (1 in 8) 12.5%
Nr tumors/rat 0 1.2 ± 0.1 (16 in 13) 0 4.0† (4 in 1)
Tumor volume (mm3)
Mean/rat 0 138.5 ± 7.5 (in 13)  0 21.2† (in 1)
Mean/tumor 0 112.5 ± 6.4 (in 16) 0 5.3 ± 0.4 (in 4)
Microscopy (qualitative) Control           BBN  CEL        CEL + BBN 
  Tumor group Total group  Tumor group Total group
Pre-neoplasic lesions
Hyperplasia 0 100 (13/13) 100 (20/20) 0 100 (1/1) 37.5 (3/8)
High-Grade Dysplasia 0 100 (13/13) 75 (15/20) 0 0 (0/1) 0 (0/8)
Low-Grade Dysplasia 0 0 (0/13) 25 (5/20) 0 100 (1/1) 12.5 (1/8)
Malignant lesions
Papillary tumor 0 100 (13/13) 65 (13/20) 0 100 (1/1) 12.5 (1/8)
Infiltrative tumor 0 15 (2/13) 10 (2/20) 0 0 (0/1) 0 (0/8)
Carcinoma In Situ 0 31 (4/13) 20 (4/20) 0 0 (0/1) 0 (0/8)
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(Fig. 3A and C, respectively). Serum TNFα (tumor necrosis factor 
α) and IL-1β (interleukin 1β) contents were unchanged between 
BBN and control rats (Fig. 3B and D, respectively). The CEL rats 
showed unchanged values of TGFβ1, increased levels of TNFα (p 
< 0.01) and IL-1β (p < 0.05) and significantly decreased contents 
of CRP (p < 0.001) (Fig. 3). When CEL was given to prevent the 
bladder cancer, the BBN-induced increment in TNFα and IL-1β 
levels was prevented (p < 0.01 and p < 0.001, respectively), while 
the other BBN-unchanged markers remained similar to those of 
the CEL group (Fig. 3).
The liver and kidney MDA (malondialdehyde) content, a 
lipidic peroxidation marker, was unchanged between the control 
and the BBN groups (Fig. 4). However, in the CEL rats there 
was a significant decrease in both liver (p < 0.05) and kidney 
(p < 0.001) MDA content. Similar profile was encountered for the 
CEL + BBN rats (Fig. 4). Serum MDA concentration showed a 
trend to higher values in the BBN group when compared with the 
control one. This value was accompanied by a significant increase 
(p < 0.05) in serum total antioxidant status (TAS). In agreement, 
serum MDA/TAS ratio, a marker of oxidative imbalance, was 
lower (trend to) than in the control rats. In the CEL animals, 
serum MDA content was reduced (p < 0.001) when compared 
with the control, TAS was unchanged and, accordingly, MDA/
TAS ratio was significantly (p < 0.05) reduced. Similar serum anti-
oxidant protection was shown for the CEL + BBN group vs. BBN 
(p < 0.001) (Fig. 4).
Biochemical and hematological data. In the BBN group, there 
were a trend to lower values of urea and higher of uric acid, when 
compared with the control group, without significant changes of 
Figure 2. Microscopic histomorphology (H&E). The bladder from control (A) and CEL (B) treated-rats had no signs of pre-neoplasic lesions or gross tumour 
formation. In the carcinogen group (C and D), the bladder from all the animals presented hyperplasia and high-grade dysplasia, including those without 
tumor formation, as well as malignant lesions, such as papillary tumors (C) and CIS (D). In the CEL + BBN group (E and F), only one bladder of the eight 
rats presented tumor formation with dysplasia (E), while all the other rats have presented a normal urothelium profile (F).
Figure 3. Serum markers of proliferation and inflammation: TGFβ1 (A), 
TNFα (B), CRP (C) and IL-1 β (D). Values are mean ± s.e.m. ap < 0.05, 
aap < 0.01 and aaap < 0.001 vs. the control group; bp < 0.05, bbp < 0.01 
and bbbp < 0.001 vs. the BBN group.
creatinine and kidney weight. An inverse profile was found for the 
CEL group. In the group under CEL + BBN treatment, all biochem-
ical renal function parameters (creatinine, urea and uric acid) 
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therapeutics effects, particularly due to the histological 
similarities it presents with the human transitional cell carci-
noma.12-14 Previous studies have shown a positive response 
to prevention strategies.16 Thus, in this study we intended 
to evaluate, using a carcinogen (BBN)-induced rat carcino-
genesis model, the efficacy of a selective COX-2 inhibitor on 
chemoprevention for tumor development and progression. 
Our results are in agreement with previous data from this 
model, concerning both % incidence of tumors and the type 
of lesions in the BBN rats,24 confirming the credibility and 
value of this model to evaluate chemopreventive efficacy of 
drugs.
It is largely accepted that the mechanisms underlying cancer 
appearance and progression are multifactorial. Inflammation, 
through its mediators (cytokines and other growth factors), 
seems to be one of the main contributors for cancer growth.25 
One of the mechanisms more closely linked to inflammation 
is the pathway of COX enzymes, in particular COX-2,19 
whose levels and activity have been reported to be elevated in 
several types of cancers.20 Furthermore, a key role for COX-2 
in carcinogenesis has been given by the positive effect of its 
downregulation on tumors incidence both in clinical and 
experimental studies for distinct types of tumors, including 
the bladder cancer.17,18,21-23,26
A chemopreventive role for COX-2 inhibition in bladder 
cancer was previously reported in animal models,26-28 but the 
mechanisms by which these compounds are able to act on 
carcinogenesis remain to be elucidated. In our study, the COX-2 
inhibitor (CEL) has promoted a remarkable chemopreventive 
effect on bladder cancer development. In fact, the incidence was 
only 12.5% (one in eight rats), with a reduced mean tumor volume 
per rat (21.2 mm3) and per tumor (5.3 ± 0.4 mm3), contrasting 
with the data from the BBN rats: 65% of tumor incidence and 
138.5 ± 7.5 and 112.5 ± 6.4 mm3 for mean tumor volume per rat 
and per tumor, respectively. Furthermore, and even more relevant, 
apart from the only rat with tumors (all papillary), whose urothe-
lium has demonstrated hyperplasia and dysplasia of low-grade, 
without infiltrative or CIS, all the other rats (seven in eight) have 
presented a normal urothelium profile (there was only low-grade 
hypertrophy in two of those seven animals), which represents a 
clear chemopreventive effect against the BBN-induced carcino-
genesis.
Several molecular mechanisms have been proposed by others 
to explain cancer development in different types of tumors.29-31 
Our data support the hypothesis that inflammation and prolif-
eration are key “fuels” for cancer progression. According to other 
authors, bladder cancer development is linked with production of 
TGFα and VEGF as mitogenic/angiogenic factor.17 In our study, 
the cancer incidence and severity reduction instigated by the 
preventive use of a selective COX-2 inhibitor was accompanied 
by a total reduction of the acute phase protein (CRP) and of the 
transforming growth factor β (TGFβ), both significantly elevated 
in the BBN group. The increment in TGFβ in the BBN group, 
which exerts a dual effect on tumor growth, as an antiproliferative 
agent in the normal epithelium and pro-invasive in the tumor,32 
is consistent with an invasive tumor phase. However, despite no 
were significantly (p < 0.01) higher than in the BBN group, as well 
as the kidney/body weights ratio (p > 0.001) (Table 2). Concerning 
liver function, AST and ALT for the BBN rats were higher (p > 
0.05) than in the control animals, as well as liver weight and liver/
body ratio (p > 0.05), contrasting with the profile of the CEL 
group, identical to the control. In the CEL + BBN group, all 
parameters were substantially lower than those of the BBN rats, 
mimicking those of the CEL rats (Table 2). Concerning haema-
tology, in the BBN rats there was a higher RBC count value (p < 
0.05) than in the control ones, a trend to elevated levels of HCT 
and a significantly lower value of WBCs (p < 0.05). In the CEL 
group, however, despite non-statistically relevance, there was a 
trend to reduced values in all the parameters for RBCs, platelets 
and WBCs. The values of the CEL + BBN rats were identical 
to those of the control animals; that is, CEL treatment in the 
BBN rats decreased the BBN-induced changes on haematological 
parameters (Table 2).
Discussion
Bladder cancer management remains a difficult mission, parti-
cularly because of the limited efficacy of the current conventional 
surgical techniques and pharmacological therapeutic options, 
especially in the control of recurrences and progressions.1,8 Thus, 
preventive strategies are needed to ameliorate bladder cancer 
management, but the exact mechanisms accounting for the cancer 
appearance and progression are yet poorly elucidate.
The carcinogen-induced bladder cancer with N-butyl-N- 
(4-hydroxybutyl) nitrosamine (BBN) in rats has been used as 
a valuable model to study bladder cancer pathophysiology and 
Figure 4. Redox status markers: lipidic peroxidation (MDA content) in liver, 
kidney and serum (A); serum TAS (B) content and serum MDA/TAS ratio (C). 
Values are mean ± s.e.m. ap < 0.05, aap < 0.01 and aaap < 0.001 vs. the 
control group; bp < 0.05, bbp < 0.01 and bbbp < 0.001 vs. the BBN group.
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idea of a key involvement of oxidative stress, together with chronic 
inflammation, in cancer development.25 In our study, the BBN 
group showed an antioxidant effect, hypothetically as a counter-
response against the formation of deleterious reactive oxygen 
species (ROS), which, thus, remained at normal levels. Anyway, 
further studies should analyze the early influence of drugs after 
the first phase of treatment (8 w) in order to elucidate if BBN is 
able to promote any relevant change (namely on COX-2 expres-
sion and activity) that could be used as earlier marker of bladder 
tumor and, furthermore, to elucidate if an earlier treatment with 
a selective COX-2 inhibitor is able to prevent it. Even thought the 
less influence of ROS formation in the carcinogenesis process, the 
positive effect of CEL seem to be extended to the redox status, 
given by the remarkable shift to the antioxidant capacity in the 
liver, kidney and serum.
In a similar work performed by Grubbs et al.,26 the effect of 
celecoxib was tested in rats under treatments in analogous condi-
tions to ours but with high concentrations of the drug (200, 
500 and 1,250 mg/kg). Since identical incidence of cancer was 
reported, our data, with a lower dose, achieves additional relevance. 
Therefore, few potential adverse effects were encountered, namely 
on the renal function, together even with a positive impact on liver 
function and hematological parameters. The increment in renal 
function markers might result from the effect of COX-2 inhibition 
on the urinary prostanoids balance. According to Gupta et al.40 
CEL treatment was able to promote tubulointerstitial nephritis, 
but using a dose three times higher than our. Therefore, Alhan 
et al.41 using a dose identical to that tested by us, did not found 
changes on renal function. In our study, when CEL was given 
alone, as a second control group, there was no relevant change 
on renal function markers, suggesting that the increment in the 
CEL + BBN group might be due to the combination of both treat-
ments (carcinogen plus drug).
changes in the carcinogen animals, both CEL groups (CEL and 
CEL + BBN) have promoted an increment in IL-1β and TNFα, 
which might hypothetically be viewed as an counter-effect of 
those treatments, independent of the carcinogenesis process but 
related with the anti-inflammatory action. The increment of 
TNFα, a multifactorial cytokine that exhibits antitumor effects 
by several mechanisms, might be viewed as part of the antitumor 
effect of CEL.33 According to other authors, CEL is able to induce 
apoptosis and reduce Bcl2, independently of COX-2 expression, 
suggesting distinct pathways for COX-2 and Bcl2.
34 Furthermore, 
they reported in the same work a 100% inhibition of proli-
feration of different doses of CEL.34 Cell cycle arrest associated 
with apoptosis is another strong hypothesis for the antitumor 
effect of COX-2 inhibitors.35 According to previous studies, the 
suppression of inflammation due to inhibition of peroxisome 
proliferator-activated receptors (PPARs) expression, which controls 
COX-2 expression, was associated with a good impact on bladder 
cancer therapy.36,37 In human bladder cancer cell lines, celecoxib 
exerted antitumor effects through mechanisms dependent and 
independent of COX-2.38
In our study, apart from the above reported anti-inflammatory 
and anti-proliferative effects, the positive impact of the selective 
COX-2 inhibitor on bladder cancer chemoprevention seems 
also to be related with a beneficial influence on redox status. In 
the carcinogen group, the tumor appearance and/or progression 
seem to be independent of impairment between the formation 
of reactive species and the antioxidants content, because liver, 
kidney and serum markers of lipidic peroxidation (MDA) were 
unchanged when compared with the control animals and serum 
total antioxidant status was even positively impacted. This data 
seem to be in opposition with the increment in MDA values 
found in humans with transitional cell carcinoma (TCC), which 
are correlated with the tumor phase,39 as well as with the general 
Table 2 Renal and liver function and hematological data
Parameters Control (n = 8) BBN (n = 20) CEL (n = 8) CEL + BBN (n = 8)
Renal function
Creatinine (µmol/L) 51.27 ± 1.77 54.81 ± 1.77 53.04 ± 1.77 64.53 ± 2.65bb
Urea (mmol/L) 13.70 ± 0.67 13.50 ± 0.47 14.71 ± 1.36 18.55 ± 0.71bb
Uric Acid (µmol/L) 36.88 ± 4.16 57.10 ± 7.14 27.96 ± 1.78 109.44 ± 14.87bb
Liver function
AST (IU/L) 51.57 ± 1.09 78.15 ± 6.04a 55.00 ± 2.71 64.57 ± 4.30bb
ALT (IU/L) 30.86 ± 1.75 38.15 ± 2.92a 28.25 ± 2.02 30.14 ± 2.58bb
Hematological data
RBC count (1012/L) 7.58 ± 0.29 8.072 ± 0.11a 7.34 ± 0.08 7.66 ± 0.10bb
HCT (pp of 0.1) 0.40 ± 0.02 0.42 ± 0.04 0.38 ± 0.04 0.40 ± 0.06
HGB (g/L) 141.50 ± 5.20 146.00 ± 1.50 132.80 ± 1.40 140.50 ± 2.00
Ret (pp of 0.1) 0.054 ± 0.002 0.052 ± 0.004 0.042 ± 0.004 0.044 ± 0.005
PLT (x109/L) 990.67 ± 46.21 1008.13 ± 46.96 884.75 ± 42.58 942.38 ± 36.89
PCT (pp of 0.1) 0.0057 ± 0.0002 0.0058 ± 0.0002 0.0053 ± 0.0002 0.0055 ± 0.0002
WBC count (109/L) 4.60 ± 0.56 3.52 ± 0.26a 2.85 ± 0.85 4.50 ± 0.44
pp, proportion. Values are mean ± s.e.m. ap < 0.05, aap < 0.01 and aaap < 0.001 vs. the control group; bp < 0.05, bbp < 0.01 and bbbp < 0.001 vs. the BBN group.
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collected by venipuncture from the jugular vein in needles with no 
anticoagulant (for serum samples collection) or with appropriated 
anticoagulant: EDTA, heparin or a solution of Acid citrate-dex-
trose, were used.
Tissues. The rats were sacrificed by cervical dislocation, and 
the lungs, stomach, liver, kidneys and intestines were immediately 
removed, weighted and placed in ice-cold Krebs buffer or form-
aldehyde. Before removal, bladders were intra-luminally injected 
with a buffered formaldehyde solution as pre-fixation for histo-
logical analyses.
Tumor chemoprevention analysis. Quantitative analysis 
(number and volume of tumors). Each bladder pre-fixated in 
formaldehyde was carefully open, the lumen was inspected for 
grossly visible lesions and the number of tumors per rat and per 
group and the volume of each tumor were reported to further 
calculate the % of tumor per group and the mean volume per rat 
and tumor.
Qualitative analysis (bladder histology). The bladder was 
immersion-fixed in 4% buffered formaldehyde and processed for 
paraffin sectioning. Three slices from each bladder were embedded. 
Three micrometer thick sections were stained with haematoxylin 
& eosin (H&E) and examined histologically by one author (Cunha 
MF) unknowing the treatments.
Proliferation, inflammation and redox status markers. Serum 
levels of transforming growth factor β-1 (TGFβ1), tumor necrosis 
factor (TNFα) and interleukin-1β (IL-1β) were measured by 
using ultrasensitive Quantikine® ELISA kits (R&D Systems, 
Minneapolis, USA). Serum C-reactive protein (CRP) was measured 
by using an ELISA kit from Helica Biosystems, Inc., (Fullerton, 
CA USA). The thiobarbituric acid reactive-species (TBARs) assay 
was used to assess serum, kidney and liver lipid peroxidation, 
namely malondialdehyde (MDA).45 The serum total antioxidant 
status (TAS) was measured through the ferric reducing antioxidant 
potential (FRAP) assay.46
Biochemical and haematological data. Renal and liver function. 
Serum creatinine, urea and uric acid concentrations were used as 
renal function indexes and serum aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) levels were assessed for hepatic 
evaluation, through automatic validated methods and equipments 
(Hitachi 717 analyser, Roche Diagnostics Inc., MA USA).
Hematological data. Red blood cell (RBC) count, haematocrit 
(HCT), hemoglobin concentration (HGB), reticulocyte count 
(RET), platelet count (PLT), plaquetocrit (PCT) and white blood 
cells (WBC) were assessed in EDTA whole-blood by using an auto-
matic Coulter Counter® (Beckman Coulter Inc., CA USA).
Statistical analysis. The Statview 4.53 software from Abacus 
Concepts Inc., (Berkeley, CA USA) was used for data analysis. 
Results are means ± S.E.M. Comparisons between groups were 
performed using one-way ANOVA and Fisher’s test. Significance 
was accepted at p less than 0.05.
Acknowledgements
The authors would like to thank Paula Neto, from the Anatomic 
Pathology of Coimbra University Hospital, for the support on the 
histomorphological procedures.
The multi-step nature of carcinogenesis provides opportuni-
ties for intervention with agents targeted at specific mechanisms 
involved in the initiation, promotion and progression stages 
of cancers.42 Inflammation, proliferation and oxidative stress 
seem to be important for bladder carcinogenesis. According to 
some authors, the formation of COX-2 are dependent on the 
degree of bladder tumor, having a pre-neoplasic action and being 
particularly elevated in more advanced phases.18,43,44 We have 
demonstrated here that the use of a selective COX-2 inhibitor in 
the stage of cancer initiation, or even before, as chemopreventive 
therapy, has a notable effect on cancer appearance and progression, 
which might be particularly useful for individuals of higher risk 
as well as for patients treated for an previous episode of bladder 
cancer and under high risk of recurrence.3,4 Further studies from 
our group will focus on testing its potential as therapy for reverse 
or retard cancer evolution, which will also be relevant for patients 
with bladder cancer with a poor prognosis considering the current 
surgical procedures and pharmacological treatments.
In conclusion, our study demonstrates that Celecoxib treat-
ment has an outstanding inhibitory effect on bladder cancer 
chemoprevention in rat, which might be due to its expected 
anti-inflammatory actions, as well as by mechanisms not directly 
dependent of COX-2 inhibition, such as cellular prolifera-
tion control and improvement in antioxidant profile. This data 
supports a pivotal role of cancer chemoprevention strategies based 
on COX-2 inhibition.
Materials and Methods
Animals and groups. Male Wistar rats (Charles River Lab. Inc., 
Barcelona, Spain), 250–285 g, were maintained in an air condi-
tioned room, subjected to 12 h dark/light cycles and given standard 
laboratory rat chow (IPM-R20, Letica, Barcelona, Spain) and free 
access to tap water. Animal experiments were conducted according 
to the “Principles of laboratory animal care.” The animals were 
divided in four groups: control group (n = 8)—vehicle (orange 
juice); carcinogen (BBN) group (n = 20)—0.05% of N-butyl-N-
(4-hydroxybutyl) nitrosamine (Tokyo Chemical Industry Co., Ltd., 
Tokyo, Japan); Celecoxib (CEL) group (n = 8)—10 mg/kg/day of 
the selective COX-2 inhibitor Celebrex® (Laboratórios Pfizer, S.a., 
Lisbon, Portugal); Preventive Celecoxib—CEL + BBN groups (n 
= 8). Treatments were performed in a two-step protocol:—a first 
period of eight weeks for tumor induction and pharmacological 
treatment (orange juice, BBN and CEL) and a second one of 12 
w for cancer expression/prevention. BBN was given in drinking 
water and orange juice (given to all groups) and CEL (prepared 
in vehicle) were given by an esophageal cannula. All the animals 
have completed the 20-w study protocol. Body weight and drink 
beverage were monitored during the experimental period.
Sample collection and preparation. Blood. At the end of 
treatments the rats were injected with intraperitoneal anesthesia 
with 2 mg/Kg BW of a 2:1 (v:v) 50 mg/mL Ketamine (Ketalar®, 
Parke-Davis, Pfizer Laboratories Lda, Seixal, Portuga) solution in 
2.5% chlorpromazine (Largatil®, Rhône-Poulenc Rorer, Vitória 
laboratories, Amadora, Portugal). Blood samples were immediately 
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